United States v. Coleman

370 F. Supp. 2d 661, 2005 U.S. Dist. LEXIS 9834, 2005 WL 1226622
CourtDistrict Court, S.D. Ohio
DecidedMay 24, 2005
DocketCR-2-02-130(1), (2), (3)
StatusPublished
Cited by24 cases

This text of 370 F. Supp. 2d 661 (United States v. Coleman) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Coleman, 370 F. Supp. 2d 661, 2005 U.S. Dist. LEXIS 9834, 2005 WL 1226622 (S.D. Ohio 2005).

Opinion

SENTENCING MEMORANDUM

MARBLEY, District Judge.

I. INTRODUCTION

The Defendants, Marilyn A. Coleman, Mitchell V. Kaminski, and Ovimmune, Inc., came before the Court for sentencing on April 29, 2005. The Court found that Defendants Coleman and Kaminski had a to *663 tal offense level of 10 and a Criminal History Category of I, resulting in a guideline imprisonment range of 6-to-12 months. The Court sentenced both Defendants to a term of probation of five years, which includes six months of confinement at a community treatment center, with work-release only, and 6 months of home confinement, which may include electronic monitoring. The Court ordered each Defendant to pay a fine of $6,000 and a special assessment of $375. In addition, all Defendants were found jointly and severally liable for restitution in the amount of $33,604.12. The Court stayed Ovim-mune’s sentence for sixty days pending resolution of certain matters. 1 In addition to outlining the sentences imposed, this Sentencing Memorandum addresses this Court’s post-Booker approach to sentencing enhancements.

II. BACKGROUND AND FACTS

A. Trial

In a 23 count Superseding Indictment, the government charged Defendants Marilyn A. Coleman (“Coleman”), Mitchell V. Kaminski (“Kaminski”), and Ovimmune, Inc. (“Ovimmune”), with one count of conspiracy, seven counts of mail fraud, and fifteen counts for violations of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. (“FDCA”). At the time of the Superceding Indictment, Defendants Coleman and Kaminski were the only active officers of the Ovimmune corporation and, together, were co-owners of the corporation. 2

The charges were based on the Defendants’ manufacture of “hyperimmune” egg products, which they allegedly sold as treatment for a variety of human diseases. These egg products were manufactured by specially vaccinating chickens, then treating the chickens’ eggs to create products referred to, inter alia, as “anti-chlamydia egg powder,” “anti-candida egg powder,” and “Candida Rx.” The theory was that the vaccinated chickens would create antibodies that would cause their eggs to be useful in treating disease. The vaccines were transported in interstate commerce. The egg products were manufactured by treating the eggs in the basement of Defendant Coleman’s home, which was listed as the business address for Defendant Ovimmune. One baggie of egg powder often sold for more than $200.

On August 15, 2002, Defendants Coleman and Kaminski were arraigned and entered pleas of not guilty. The Defendants denied all of the government’s allegations, claiming: (1) their products were not drugs; (2) they lacked the criminal intent necessary under federal law; and (3) they acted in reasonable reliance on the government’s assertions that their conduct was lawful. The trial began June 23, 2003, and lasted nineteen days. After four days of deliberations, on July 23, 2003, the jury reached a verdict.

The jury found all three Defendants not guilty of the crime of conspiracy in violation of 18 U.S.C. § 371 as charged in Count 1 of the Superseding Indictment and not guilty of the crimes of mail fraud in violation of 18 U.S.C. §§ 2 and 1341 as charged in Counts 2 through 8. As to Counts 9 through 13, introduction into interstate commerce of unapproved new drugs in violation of 21 U.S.C. §§ 331(d), 355(a) and 333(a)(2) and 18 U.S.C. § 2, the *664 jury found that the Defendants did not have the intent to defraud or mislead required for felony violations, but did find them guilty of the lesser included offenses of introduction into interstate commerce of unapproved new drugs without intent to defraud or mislead, misdemeanor offenses.

As to Counts 14 through 17, introduction of misbranded drugs into interstate commerce in violation of 21 U.S.C. §§ 331(a) and 333(a)(2) and 18 U.S.C. § 2, the jury found that the Defendants did not have the intent to defraud or mislead required to find felony violations, but found them guilty of the lesser included offenses of introduction into interstate commerce of misbranded drugs without intent to defraud or mislead, misdemeanor offenses. The jury specifically found “misbranding” by virtue of the fact both that (1), the product’s labeling did not bear adequate directions for use, and (2) the product was manufactured, prepared, propagated, compounded, or processed in an establishment in any state not duly registered with the Food and Drug Administration (“FDA”).

As to Count 18, failure to register a drug manufacturing facility in violation of 21 U.S.C. §§ 331(p) and 333(a)(2) and 18 U.S.C. § 2, the jury found that the Defendants did not have the intent to defraud or mislead required to find a felony violation, but found them guilty of the lesser included offense of failure to register a drug-manufacturing facility without intent to defraud or mislead, a misdemeanor.

As to Counts 19 through 21, misbrand-ing drugs while held for sale after shipment in interstate commerce in violation of 21 U.S.C. §§ 331(k) and 333(a)(2) and 18 U.S.C. § 2, the jury found that the Defendants did not have the intent to defraud or mislead required to find felony violations, but did find them guilty of the lesser in~ cluded offenses of misbranding drugs while held for sale after shipment in interstate commerce without intent to defraud or mislead, misdemeanor offenses.

The jury found the Defendants guilty as charged in Counts 22 and 23, adulterating drugs in violation of 21 U.S.C. §§ 331(k)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Scheiblich
346 F. Supp. 3d 1076 (S.D. Ohio, 2018)
United States v. Quality EGG, LLC
99 F. Supp. 3d 920 (N.D. Iowa, 2015)
United States v. Sen
24 F. Supp. 3d 732 (E.D. Tennessee, 2014)
Commonwealth v. Stokes
38 A.3d 846 (Superior Court of Pennsylvania, 2011)
State v. Witmer
2011 ME 7 (Supreme Judicial Court of Maine, 2011)
United States v. Brika
Sixth Circuit, 2007
United States v. Ahmed Brika
487 F.3d 450 (Sixth Circuit, 2007)
United States v. Zuni
506 F. Supp. 2d 663 (D. New Mexico, 2007)
United States v. Vigil
476 F. Supp. 2d 1231 (D. New Mexico, 2007)
United States v. Sean Michael Grier
475 F.3d 556 (Third Circuit, 2007)
United States v. Grier
Third Circuit, 2007
United States v. Mercado
Ninth Circuit, 2007
United States v. Farias
469 F.3d 393 (Fifth Circuit, 2006)
United States v. Ibanga
454 F. Supp. 2d 532 (E.D. Virginia, 2006)
United States v. Kandirakis
441 F. Supp. 2d 282 (D. Massachusetts, 2006)
United States v. Neal
177 F. App'x 220 (Third Circuit, 2006)
United States v. Edwards
427 F. Supp. 2d 17 (District of Columbia, 2006)
United States v. Wendelsdorf
423 F. Supp. 2d 927 (N.D. Iowa, 2006)
United States v. Santiago
413 F. Supp. 2d 307 (S.D. New York, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
370 F. Supp. 2d 661, 2005 U.S. Dist. LEXIS 9834, 2005 WL 1226622, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-coleman-ohsd-2005.